Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

Inclusion Criteria:

• Patients with high-risk myeloid or lymphoid malignancies determined to be eligibleto undergo a related, allo-SCT using Disease Risk Index (DRI), including theconditions listed below. These criteria apply BEFORE cyto-reductive therapy givenwithin 28 days of planned conditioning:

• Refractory acute myelogenous or lymphoid leukemia

• Relapsed acute myelogenous or lymphoid leukemia

• Myelodysplastic syndromes with 5 percent or more blasts

• Chronic myelogenous leukemia in chronic phase 3 or more, blast phase presently,or second accelerated phase

• Recurrent or refractory malignant lymphoma or Hodgkin's disease with less thana partial response at transplant

• High risk chronic lymphocytic leukemia defined as no response or stable diseaseto the most recent treatment regimen

• Other high risk hematologic malignancies for which allo-SCT is deemedclinically necessary per PI and based on institutional standards

• The donor for the allo-SCT will have been identified prior to participantrecruitment and must be:

• Related AND

• Matched OR mismatched OR haploidentical at Human Leukocyte Antigen (HLA) HLA-A, -B, -C, and -DRB1 by molecular methods

• Eastern Cooperative Oncology Group (ECOG) performance score of 0-2

• Ability to understand and willingness to sign written informed consent document

• Willing to comply with all study procedures and be available for the duration of thestudy

• Individuals in sexual relationships that could result in pregnancy or impregnationof their partner must use an acceptable method of contraception§ from enrollmentuntil 4 weeks after completing study treatment.

Exclusion Criteria:

• Poor organ function as follows (According to the pre-transplant workups results):

• Creatinine greater than or equal to 2.0 mg/dL

• Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic PyruvicTransaminase (SGPT) greater than or equal to 5 x Upper Limit of Normal (ULN).Liver biopsy per clinician discretion.

• Bilirubin greater than or equal to 3 x ULN (unless Gilbert's syndrome)

• Diffusing capacity of the Lungs for Carbon Monoxide (DLCO) less than 50 percentcorrected for hemoglobin

• Left ventricular ejection fraction or shortening fraction less than 40 percent

NOTE: Exceptions to the above organ function exclusion criteria are allowable only with assent of the PI since the risks and benefits must be addressed for patients with potentially incurable hematologic malignancies. Such exceptions will be clearly documented in the subject's research record and will not be considered a deviation.

• Patients with uncontrolled intercurrent illness

• Patients with psychiatric illness/social situations that would limit compliance withstudy requirements